GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bolt Biotherapeutics BOLT · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.91

-2.96%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Bolt Biotherapeutics — daily BOLT Delayed
Market value
$9.4m
Last close × shares
Volume
60.5k
Shares, 20 Nov 2026

About Bolt Biotherapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Bolt Biotherapeutics is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BOLT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $7.7m and a net loss of $33.4m. At that date it held total assets of $56.7m and shareholders' equity of $26.5m.

In its own words

BDC-4182 is a next-generation Boltbody™ ISAC that targets the tumor-associated antigen claudin 18.2. Claudin 18.2 is a clinically validated target in oncology with zolbetuximab, a claudin 18.2-targeted monoclonal antibody, approved in Japan, the U.S., and other countries for the treatment of patients with claudin 18.2-positive, unresectable, advanced or recurrent gastric cancer in combination with chemotherapy. Other programs targeting claudin 18.2 are in development for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. BDC-4182 is supported by in vitro and in vivo experiments demonstrating potent anti-tumor activity in multiple preclinical models, safety and tolerability in toxicology studies, and enhanced anti-tumor activity compared to cytotoxic antibody-drug conjugates, or ADCs, in murine tumor models. Data on our claudin 18.2 Boltbody ISAC program was presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meetings in November 2025, 2024 and 2023. The first-in-human Phase 1 dose escalation trial of BDC-4182 is ongoing in subjects with gastric/gastroesophageal junction cancer.

Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗

More about Bolt Biotherapeutics →

Latest on Bolt Biotherapeutics

Our reporting

Next results

11 Mar 2027

Due on 11 Mar 2027. Analysts expect earnings of -2.01 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Bolt Biotherapeutics's ticker?

Bolt Biotherapeutics trades as BOLT on its US listing, under ISIN US0977022039.

What was Bolt Biotherapeutics's last closing price?

4.91 on 20 Nov 2026. The figure is in USD and is never converted.

When does Bolt Biotherapeutics next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.